Charles Kummeth is recorded as CEO at BIO-TECHNE Corp (TECH), Board Member at Quantum-Si Inc (QSI) since May 27, 2024 and Chairman at Quantum-Si Inc (QSI). The newest filing on record that lists Charles Kummeth as CEO at BIO-TECHNE Corp (TECH) is dated September 14, 2021. The newest filing on record that lists Charles Kummeth as Chairman at Quantum-Si Inc (QSI) is dated April 1, 2026. Charles Kummeth was last confirmed as Board Member at Gentherm Inc (THRM) in a filing dated March 27, 2025. Quantum-Si Inc reported in an 8-K filed May 30, 2024 that Charles Kummeth was appointed Board of Directors, effective May 27, 2024. Quantum-Si Inc reported in an 8-K filed May 30, 2024 that Charles Kummeth was appointed Chairperson of the Board, effective May 27, 2024. Gentherm Inc reported in an 8-K filed May 18, 2023 that Charles Kummeth was appointed director, effective May 18, 2023. The proxy statement of BIO-TECHNE Corp reports total compensation of $6,792,945 for Charles Kummeth in fiscal 2024, including a base salary of $1,184,200. Disclosed compensation is on record for 7 fiscal years. Charles Kummeth has spoken on 4 earnings calls across 1 company, most recently for BIO-TECHNE Corp on February 1, 2024. BIO-TECHNE Corp is classified in the Biotechnology industry within the Healthcare sector. Quantum-Si Inc is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at BIO-TECHNE Corp includes James T. Hippel (CFO), Kim Kelderman (COO and Board Member), Shane Bohnen (General Counsel) and 7 others.
“On May 27, 2024, the Board of Directors (the “Board”) of Quantum-Si Incorporated (the “Company”) elected Charles (“Chuck”) Kummeth to the Board and appointed him as Chairperson of the Board, each effective as of May 27, 2024 (the “Effective Date”).”
Quantum-Si Inc Form 8-K, filed May 30, 2024
· Read the filing
“On May 27, 2024, the Board of Directors (the “Board”) of Quantum-Si Incorporated (the “Company”) elected Charles (“Chuck”) Kummeth to the Board and appointed him as Chairperson of the Board, each effective as of May 27, 2024 (the “Effective Date”).”
Quantum-Si Inc Form 8-K, filed May 30, 2024
· Read the filing
Charles Kummeth on recent calls
“As many of you know, my official tenure as Bio-Techne's Chief Executive Officer ended yesterday, and Kim Kelderman is now in this leadership role. He's taking over a company that is incredibly well-positioned in several of the highest growth life science and diagnostic end markets.”
“The Bio-Techne team continues to execute in a challenging environment as we delivered 2% organic growth for the first quarter of fiscal 2024 despite several headwinds that are impacting the broader industry as well as Bio-Techne.”
“Our organic revenue growth in the second quarter increased 6% year-over-year, although adjusting for the impact of certain timing headwinds, our underlying organic growth was closer to our year-to-date growth of approximately 10%.”
“We started fiscal 2020 on a strong note with our first quarter organic revenue increasing 13% year-over-year, continuing a double-digit organic growth rate we delivered in fiscal 2019.”
